-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, there have been news of a large number of pharmacies being fined for publishing false advertisements, circumventing normal sales channels, selling prescription drugs without prescriptions, and not issuing sales vouchers, e.
, which has once again sounded the alarm for the industry: these "red lines" cannot be touched! Among them, since May, 11 pharmacies in Hainan have been fin.
The drug administrative punishment case disclosed by the Provincial Food and Drug Administration shows that on May 20, three pharmacies were fined 600 yuan each for selling prescription drugs without prescripti.
On May 20, six pharmacies were each fined 300 yuan for not issuing sales certificates; on May 5, three pharmacies were each fined 300 yu.
On May 25, it was reported that Yantai City, Shandong Province recently launched a special rectification action for drug safe.
Among them, two pharmacies purchased two OTC drugs from the same manufacturer and sold them to patients in Yantai through a sales platfo.
In the process of purchasing drugs, the two pharmacies failed to implement the inspection and acceptance system, did not ask for purchase invoices, did not record the purchase and sales of the above two drugs, and did not issue sales vouchers for the sales of these two drugs, making it impossible to trace the flow of dru.
The above behavior seriously violated the "Quality Management Regulations for Pharmaceutical Business", and the two pharmacies were each fined 500,000 yuan and their "Drug Business License" was revok.
At the same time, the relevant departments also punished the heads of the two pharmacy enterprises with "banning drug production and business activities within 10 year.
Recently, a company affiliated to a pharmacy in Beijing was notified by the Guangzhou Municipal Market Supervision Bureau as the "first batch of typical cases of illegal advertisements in 2022" for publishing illegal drug advertisemen.
According to the report, in order to promote the prescription drugs it operates, the company published an advertisement for the prescription drug "Sildenafil Citrate Tablets" (restricted release) without authorization on the product display page of its online store on a website platform, which violated the Advertising L.
According to the regulations, Guangzhou Yuexiu District Municipal Supervision Bureau ordered it to stop publishing illegal advertisements and imposed an administrative penalty of 260,000 yu.
Not long ago, the Hubei Provincial Market Supervision Bureau also announced the first batch of typical cases of illegal advertisements to be investigated and dealt with in 2022, including a pharmacy that was "ordered to stop publishing illegal advertisements and fined 200,000 yuan" for publishing false advertising twee.
A pharmacy in Shenzhen also recently reported that it was fined 1,000 yuan because the pharmacy violated the regulations on the classification and placement of drugs, and many companies under the pharmacy have also been punished for different illegal ac.
Drugs are special commodities that are related to human health, and safety issues cannot be ignor.
In recent years, China has attached great importance to drug safety issues, especially the implementation of the new version of the Drug Administration Law, which has greatly increased the cost of violations by pharmaceutical companies, and increased the penalties for pharmaci.
" streng.
The new version of the "Drug Administration Law" stipulates that if the company fails to comply with the quality management standards for drug distribution, and the circumstances are serious, the legal representative, main responsible person, directly responsible person in charge and other responsible personnel of the enterprise shall receive more than 10% of the inco.
A fine of not more than 50%, and a ban on drug production and business activities for ten years or even li.
In addition, the "14th Five-Year Plan for National Drug Safety and Promotion of High-Quality Development" has made "improving the drug safety governance system" one of the main tas.
"If you want to know the straight, you must have a standard; if you want to know the square, you must be disciplin.
" With the continuous improvement of laws and regulations, and the increasing supervision, pharmaceutical companies need to regulate their operations in order to go furth.
Click to enter the exhibition page
, which has once again sounded the alarm for the industry: these "red lines" cannot be touched! Among them, since May, 11 pharmacies in Hainan have been fin.
The drug administrative punishment case disclosed by the Provincial Food and Drug Administration shows that on May 20, three pharmacies were fined 600 yuan each for selling prescription drugs without prescripti.
On May 20, six pharmacies were each fined 300 yuan for not issuing sales certificates; on May 5, three pharmacies were each fined 300 yu.
On May 25, it was reported that Yantai City, Shandong Province recently launched a special rectification action for drug safe.
Among them, two pharmacies purchased two OTC drugs from the same manufacturer and sold them to patients in Yantai through a sales platfo.
In the process of purchasing drugs, the two pharmacies failed to implement the inspection and acceptance system, did not ask for purchase invoices, did not record the purchase and sales of the above two drugs, and did not issue sales vouchers for the sales of these two drugs, making it impossible to trace the flow of dru.
The above behavior seriously violated the "Quality Management Regulations for Pharmaceutical Business", and the two pharmacies were each fined 500,000 yuan and their "Drug Business License" was revok.
At the same time, the relevant departments also punished the heads of the two pharmacy enterprises with "banning drug production and business activities within 10 year.
Recently, a company affiliated to a pharmacy in Beijing was notified by the Guangzhou Municipal Market Supervision Bureau as the "first batch of typical cases of illegal advertisements in 2022" for publishing illegal drug advertisemen.
According to the report, in order to promote the prescription drugs it operates, the company published an advertisement for the prescription drug "Sildenafil Citrate Tablets" (restricted release) without authorization on the product display page of its online store on a website platform, which violated the Advertising L.
According to the regulations, Guangzhou Yuexiu District Municipal Supervision Bureau ordered it to stop publishing illegal advertisements and imposed an administrative penalty of 260,000 yu.
Not long ago, the Hubei Provincial Market Supervision Bureau also announced the first batch of typical cases of illegal advertisements to be investigated and dealt with in 2022, including a pharmacy that was "ordered to stop publishing illegal advertisements and fined 200,000 yuan" for publishing false advertising twee.
A pharmacy in Shenzhen also recently reported that it was fined 1,000 yuan because the pharmacy violated the regulations on the classification and placement of drugs, and many companies under the pharmacy have also been punished for different illegal ac.
Drugs are special commodities that are related to human health, and safety issues cannot be ignor.
In recent years, China has attached great importance to drug safety issues, especially the implementation of the new version of the Drug Administration Law, which has greatly increased the cost of violations by pharmaceutical companies, and increased the penalties for pharmaci.
" streng.
The new version of the "Drug Administration Law" stipulates that if the company fails to comply with the quality management standards for drug distribution, and the circumstances are serious, the legal representative, main responsible person, directly responsible person in charge and other responsible personnel of the enterprise shall receive more than 10% of the inco.
A fine of not more than 50%, and a ban on drug production and business activities for ten years or even li.
In addition, the "14th Five-Year Plan for National Drug Safety and Promotion of High-Quality Development" has made "improving the drug safety governance system" one of the main tas.
"If you want to know the straight, you must have a standard; if you want to know the square, you must be disciplin.
" With the continuous improvement of laws and regulations, and the increasing supervision, pharmaceutical companies need to regulate their operations in order to go furth.
Click to enter the exhibition page
